1 |
Pinzani M, Rosselli M, Zuckermann M, et al.Liver cirrhosis [J]. Best Pract Res Clin Gastroenterol, 2011, 25(2): 281-290.
|
2 |
Liu SL, Premont RT, Kontos CD, et al.A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension[J]. Nat Med, 2005, 11(9): 952-958.
|
3 |
Matei V, Rodríguez-Vilarrupla A, Deulofeu R, et al.The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis[J]. Hepatology, 2006, 44(1): 44-52.
|
4 |
Rockey DC, Chung JJ.Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension[J]. Gastroenterology, 1998, 114(2): 344-351.
|
5 |
Marrone G, Maeso-Díaz R, García-Cardena G, et al.KLF2 exerts anti?brotic and vasoprotective effects in cirrhotic rat livers: livers behind the molecular mechanisms of statins [J]. Gut, 2014, 64(9): 1434-1443.
|
6 |
Marrone G, Russo L, Rosado E, et al.The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins[J]. Hepatol, 2013, 58: 98-103.
|
7 |
Uschner FE, Ranabhat G, Choi SS, et al.Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension [J]. Scientific RepoRts, 2015, 5: 14573.
|
8 |
Zafra C, Abraldes JG, Turnes J, et al.Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis [J]. Gastroenterology, 2004, 126(3): 749-755.
|
9 |
Abraldes JG, Albillos A, Bañares R, et al.Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial [J]. Gastroenterology, 2009, 136(5): 1651-1658.
|
10 |
Pollo-Flores P, Soldan M, Santos UC, et al.Three months of simvastatin therapy vs.placebo for severe portal hypertension in cirrhosis: A randomized controlled trial [J]. Dig Liver Dis, 2015, 47(11): 957-963.
|
11 |
Atar S, Cannon CP, Murphy SA, et al.Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: Analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16(OPUS-TIMI 16)trial [J]. AHJ, 2006, 151(5): 976.e1-e6.
|
12 |
Huang HC, Wang SS, Lee JY, et al.Simvastatin effects on portal-systemic collaterals of portal hypertensive rats [J]. J Gastroenterol Hepatol, 2010, 25(8): 1401-1409.
|
13 |
Gulmez SE, Lassen AT, Aalykke C, et al.Do statins protect against upper gastrointestinal bleeding? [J]. Br J Clin Pharmacol, 2009, 67(4): 460-465.
|
14 |
Trebicka J, Hennenberg M, Odenthal M, et al.Atorvastatin attenuates hepatic?brosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells [J]. J Hepatol, 2010, 53(4): 702-712.
|
15 |
Abel T, Fehér J, Dinya E, et al.Safety and efficacy of combined ezetemibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease [J]. Med Sci Monit, 2009, 15(12): MS6-MS11.
|
16 |
Samy W, Hassanian MA.Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin [J]. Arab J Gastroenterol, 2011, 12(2): 80-85.
|
17 |
Kalinowski L, Dobrucki LW, Brovkovych V, et al.Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic efect of cerivastatin[J]. Circulation, 2002, 105(8): 933-938.
|
18 |
Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase [J]. Science, 2001, 292(5519): 1160-1164.
|
19 |
Motzkus-Feagans C, Pakyz AL, Ratliff SM, et al.Statin use and infections in veterans with cirrhosis[J]. Aliment Pharmacol Ther, 2013, 38(6): 611-618.
|
20 |
Abraldes JG, Villanueva C, Aracil C, et al.Addition of simvastatin to standard treatment improves survival after variceal bleeding in patients with cirrhosis.A doubleblind randomized trial[J]. J Hepatol, 2014, 150(5): 1160-1170.e3.
|
21 |
Rehenxiann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection [J]. Nat Rev Immunol, 2005, 5(3): 215-229.
|
22 |
Shi M, Zheng H, Nie B, et al.Statin use and risk of liver cancer: an update meta-analysis [J]. BMJ Open, 2014, 4(9): e005399.
|
23 |
Hsiang JC, Wong GL, Tse YK, et al.Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis [J]. J Hepatol, 2015, 63(5): 1190-1197.
|
24 |
El-Serag HB, Johnson ML, Hachem C, et al.Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes [J]. Gastroenterology, 2009, 136(5): 1601-1608.
|
25 |
Dale KM, Coleman CI, Henyan NN, et al.Statins and cancer risk: a Meta-analysis [J]. JAMA, 2010, 304(23): 2559-2658.
|
26 |
Forrester JS, Libby P. The infammation hypothesis and its potential relevance to statin therapy[J]. Am J Cardiol, 2007, 99(5): 732-738.
|
27 |
Chang CY, Schiano TD.Review article: Drug hepatotoxicity[J]. Aliment Pharmacol Ther, 2007, 25(10): 1135-1151.
|
28 |
Avins AL, Manos MM, Ackerson L, et al.Hepatic efects of lovastatin exposure in patients with liver disease: a retrospective cohort study [J]. Drug Saf, 2008, 31(4): 325-334.
|
29 |
Sonal K, Grace ND, Qamar AA.Statin use in patients with cirrhosis: A retrospective cohort study[J]. Dig Dis Sci, 2014, 59(8): 1958-1965.
|
30 |
Bottorff M B. Statin safety and drug interactions: clinical implications [J]. Am J Cardiol, 2006, 97(8A): 27C-31C.
|
31 |
Souk K, Al-Badri M, Azar ST.The Safety and Beneft of Statins in Liver Cirrhosis: a Review [J]. Exp Clin Endocrinol Diabetes, 2015, 123(10): 577-580.
|